Literature DB >> 28427578

Implantable Cardioverter-Defibrillators With Versus Without Resynchronization Therapy in Patients With a QRS Duration >180 ms.

Varun Sundaram1, Jayakumar Sahadevan2, Albert L Waldo3, George J Stukenborg4, Yogesh N V Reddy5, Samuel J Asirvatham5, Judith A Mackall3, Anselma Intini6, Brigid Wilson6, Daniel I Simon3, Kenneth C Bilchick4.   

Abstract

BACKGROUND: More than 20% of Medicare beneficiaries receiving cardiac resynchronization therapy defibrillators (CRT-D) have a very wide (≥180 ms) QRS complex duration (QRSD). Outcomes of CRT-D in these patients are not well-established because they have been underrepresented in clinical trials.
OBJECTIVES: This study examined outcomes in patients with CRT-D in a very wide QRSD with left bundle branch block (LBBB) versus those without LBBB.
METHODS: Medicare patients from the Implantable Cardioverter Defibrillator Registry (January 1, 2005, through April 30, 2006) with a CRT-D and confirmed Class I or IIa indications for CRT-D were matched to implantable cardioverter-defibrillator (ICD) patients without CRT despite having Class I or IIa indications for CRT. Mortality and heart failure hospitalizations longer than 4 years with CRT-D versus standard ICDs based on a QRSD and morphology were analyzed.
RESULTS: We analyzed 24,960 patients. Among those with LBBB, patients with a QRSD ≥180 ms had a greater adjusted survival benefit with CRT-D versus standard ICD (hazard ration [HR] for death: 0.65; 95% confidence interval [CI]: 0.59 to 0.72) compared with those having a QRSD 120 to 149 ms (HR: 0.85; 95% CI: 0.80 to 0.92) and 150 to 179 ms (HR: 0.87; 95% CI: 0.81 to 0.93). CRT-D versus ICD was associated with an improvement in survival in those with LBBB and a QRSD ≥180 ms (adjusted HR for death: 0.78; 95% CI: 0.68 to 0.91), but not in those with LBBB and a QRSD 150 to 179 ms (adjusted HR for death: 1.06; 95% CI: 0.95 to 1.19).
CONCLUSIONS: Improvements in both survival and heart failure hospitalizations with CRT-D were greatest in patients with a QRSD ≥180 ms with or without LBBB, whereas patients with a QRSD 150 to 179 ms without LBBB had no improvement in survival with CRT-D, and those with a QRSD 150 to 179 ms and LBBB had only a modest improvement. Published by Elsevier Inc.

Entities:  

Keywords:  bundle branch block; cardiac resynchronization therapy; heart failure; outcomes; very wide QRS complex

Mesh:

Year:  2017        PMID: 28427578      PMCID: PMC6834434          DOI: 10.1016/j.jacc.2017.02.042

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

1.  Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores.

Authors:  S T Normand; M B Landrum; E Guadagnoli; J Z Ayanian; T J Ryan; P D Cleary; B J McNeil
Journal:  J Clin Epidemiol       Date:  2001-04       Impact factor: 6.437

2.  Competing risk of death: an important consideration in studies of older adults.

Authors:  Sarah D Berry; Long Ngo; Elizabeth J Samelson; Douglas P Kiel
Journal:  J Am Geriatr Soc       Date:  2010-03-22       Impact factor: 5.562

3.  2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management.

Authors:  Jean-Claude Daubert; Leslie Saxon; Philip B Adamson; Angelo Auricchio; Ronald D Berger; John F Beshai; Ole Breithard; Michele Brignole; John Cleland; David B DeLurgio; Kenneth Dickstein; Derek V Exner; Michael Gold; Richard A Grimm; David L Hayes; Carsten Israel; Christophe Leclercq; Cecilia Linde; JoAnn Lindenfeld; Bela Merkely; Lluis Mont; Francis Murgatroyd; Frits Prinzen; Samir F Saba; Jerold S Shinbane; Jagmeet Singh; Anthony S Tang; Panos E Vardas; Bruce L Wilkoff; Jose Luis Zamorano; Inder Anand; Carina Blomström-Lundqvist; John P Boehmer; Hugh Calkins; Serge Cazeau; Victoria Delgado; N A Mark Estes; David Haines; Fred Kusumoto; Paco Leyva; Frank Ruschitzka; Lynne Warner Stevenson; Christian Tobias Torp-Pedersen
Journal:  Europace       Date:  2012-09       Impact factor: 5.214

4.  2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Cynthia M Tracy; Andrew E Epstein; Dawood Darbar; John P Dimarco; Sandra B Dunbar; N A Mark Estes; T Bruce Ferguson; Stephen C Hammill; Pamela E Karasik; Mark S Link; Joseph E Marine; Mark H Schoenfeld; Amit J Shanker; Michael J Silka; Lynne Warner Stevenson; William G Stevenson; Paul D Varosy
Journal:  J Am Coll Cardiol       Date:  2012-09-10       Impact factor: 24.094

5.  Agreement is poor among current criteria used to define response to cardiac resynchronization therapy.

Authors:  Brandon K Fornwalt; William W Sprague; Patrick BeDell; Jonathan D Suever; Bart Gerritse; John D Merlino; Derek A Fyfe; Angel R León; John N Oshinski
Journal:  Circulation       Date:  2010-04-26       Impact factor: 29.690

Review 6.  Defining left bundle branch block in the era of cardiac resynchronization therapy.

Authors:  David G Strauss; Ronald H Selvester; Galen S Wagner
Journal:  Am J Cardiol       Date:  2011-03-15       Impact factor: 2.778

7.  Impact of mechanical activation, scar, and electrical timing on cardiac resynchronization therapy response and clinical outcomes.

Authors:  Kenneth C Bilchick; Sujith Kuruvilla; Yasmin S Hamirani; Raghav Ramachandran; Samantha A Clarke; Katherine M Parker; George J Stukenborg; Pamela Mason; John D Ferguson; J Randall Moorman; Rohit Malhotra; J Michael Mangrum; Andrew E Darby; John Dimarco; Jeffrey W Holmes; Michael Salerno; Christopher M Kramer; Frederick H Epstein
Journal:  J Am Coll Cardiol       Date:  2014-03-05       Impact factor: 24.094

8.  Competing risk regression models for epidemiologic data.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2009-06-03       Impact factor: 4.897

Review 9.  Gap junction remodeling in heart failure.

Authors:  Nicholas J Severs
Journal:  J Card Fail       Date:  2002-12       Impact factor: 5.712

10.  Comparative effectiveness of cardiac resynchronization therapy in combination with implantable defibrillator in patients with heart failure and wide QRS duration.

Authors:  Kenneth C Bilchick; George J Stukenborg
Journal:  Am J Cardiol       Date:  2014-08-27       Impact factor: 2.778

View more
  5 in total

1.  Non-invasively quantified changes in left ventricular activation predict outcomes in patients undergoing cardiac resynchronization therapy.

Authors:  Daniel J Friedman; Kasper Emerek; Steen Møller Hansen; Christoffer Polcwiartek; Peter L Sørensen; Zak Loring; Joanne Sutter; Peter Søgaard; Joseph Kisslo; Claus Graff; Brett D Atwater
Journal:  J Cardiovasc Electrophysiol       Date:  2019-10-08

Review 2.  The Treatment of Heart Failure with Reduced Ejection Fraction.

Authors:  Dominik Berliner; Anja Hänselmann; Johann Bauersachs
Journal:  Dtsch Arztebl Int       Date:  2020-05-22       Impact factor: 5.594

Review 3.  Cardiac Resynchronization Therapy-Emerging Therapeutic Approaches.

Authors:  Neal A Chatterjee; E Kevin Heist
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-06

4.  Device therapy in heart failure with reduced ejection fraction-cardiac resynchronization therapy and more.

Authors:  D Duncker; C Veltmann
Journal:  Herz       Date:  2018-08       Impact factor: 1.443

5.  Multisite cardiac resynchronization therapy for traditional and non-traditional indications.

Authors:  Avishag Laish-Farkash; Sharon Bruoha; Vladimir Khalameizer; Chaim Yosefy; Yoav Michowitz; Mahmoud Suleiman; Amos Katz
Journal:  J Interv Card Electrophysiol       Date:  2018-02-13       Impact factor: 1.900

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.